Blanco-Silvente L, et al. - Researchers determined the risk-benefit association of memantine treatment in Alzheimer’s disease (AD) patients, as well as the predictor effect of patient, intervention, and study design related covariates, via meta-analysis and meta-regression of 18 randomized clinical trials involving 5,004 patients. Regarding AD symptomatology, memantine showed a very minor effectiveness. A similar safety profile of memantine was observed with that of placebo. No evidence of treatment discontinuation improvement with memantine was seen, which suggested a dubious risk-benefit association. A significantly better risk-benefit association was not clearly demonstrated by any intervention characteristic or subgroup of patients.